MDNA Life Sciences Inc. (MDLS)
| Market Cap | n/a |
| Revenue (ttm) | 3.60M |
| Net Income (ttm) | -3.79M |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About MDLS
MDNA Life Sciences is a life sciences company focused on the development of liquid biopsy tests based on the mitochondrial genome. We have discovered novel biomarkers and designed laboratory assays, which we refer to as our Mitomic Technology, that are intended to use mitochondrial DNA to detect cancer earlier, more accurately, and less invasively than traditional methods. Though we have no commercially available FDA or foreign regulator approved products, we have licensed our intellectual property related to the Mitomic prostate cancer biomark... [Read more...]
Financial Performance
In 2020, MDLS's revenue was $106,009, a decrease of -97.06% compared to the previous year's $3.60 million. Losses were -$4.57 million, 52.2% more than in 2021.
Financial StatementsNews
US IPO Weekly Recap: August Kicks off with a 2 IPO week
Two deals priced this week, but only one met the criteria to be included in our 2022 IPO stats. Four new filings, including two offering units, also trickled into the pipeline.
MDNA Life Sciences IPO Registration Document (S-1)
MDNA Life Sciences has filed to go public with an IPO on the NASDAQ.